Affymetrix Inc

Affymetrix — Merger or Acquisition (May 2005)

56 slides from Affymetrix's merger presentation, May 31, 2005

  1. Slide 1: Forward Looking Statements

    Forward Looking Statements All statements in this presentation that are not historical are "forward-looking statements" within the meaning of Section 21E of the Securities Exchange Act as amended, including statements regarding Affymetrix' "expectations," "beliefs," "hopes," "intentions," "strategie

  2. Slide 2: Important Information For ParAllele Investors And Shareholders

    Important Information For ParAllele Investors And Shareholders Affymetrix will file a registration statement on Form S-4 containing a prospectus with the SEC in connection with its proposed acquisition of ParAllele. Affymetrix urges ParAlleles investors and shareholders to read these documents when

  3. Slide 3: Agenda

    Agenda o Affymetrix: The Company o The Power of Photolithography o Products o Customers, Markets, & Business Models o Working Together o Human Resources o Next Steps and Q&A

  4. Slide 4: Milestones in Affymetrix Evolution

    Milestones in Affymetrix Evolution

  5. Slide 5: Milestones in Affymetrix Evolution

    lestones in Affymetrix Evolution Toor T war Tvo00 T toon T toon T rose T war 1 vo0e Twos T 2op0 T avon 1 2002 T 2000 1 2008 17 2008 sereicrn, oa KO: 7] or ee enor sa “se

  6. Slide 6: Global Infrastructure

    Global Infrastructure o Headquartered in Santa Clara, CA o NASDAQ: AFFX (IPO in 1996) o Employees ~ 900

  7. Slide 7: Affymetrix & ParAllele: Shared Mission

    Affymetrix & ParAllele: Shared Mission! Affymetrix Corporate Mission To be the leading source of molecular technologies to understand and improve life. Mission Statement ParAllele ParAllele will be the leading supplier of innovative solutions for understanding how genetic variation impacts human hea

  8. Slide 8: Historic Financial Performance

    Historic Financial Performance o Installed base > 1200 instruments worldwide o Over 500,000 chips shipped in 2004 o >300 patents issued o 3000 peer reviewed papers

  9. Slide 9: Historic Financial Performance

    Historic Financial Performance The Wey Ahoad™ 0 $125 (ears reve lmmctrcoe 059 Oo) Lees = 75 20 =) 025 = a rn se = a er) > om $0.25 ex om $079 00) = $0125

  10. Slide 10: Agenda

    Agenda o Affymetrix: The Company o The Power of Photolithography o Products o Customers, Markets, & Business Models o Working Together o Human Resources o Next Steps and Q&A

  11. Slide 11: Affymetrix: The Company

    Affymetrix: The Company The Power of Photolithography Products Customers, Markets, & Business Models Working Together Human Resources Next Steps and Q&A

  12. Slide 12: Arrays, Chips, and Features

    APEYUETAYS KYO. Chips/wafer 41.28cm 1.28cm Up to ~1,300,000 features /chip rs, Chips, and Features Millions of identical probes /feature

  13. Slide 13: Moore's Law - Array Information Capacity

    Moore's Law - Array Information Capacity

  14. Slide 14: GMP Compliant and ISO/QSR Certified GeneChip Probe Array Manufacturing

    GMP Compliant and ISO/QSR Certified GeneChip® Probe Array Manufacturing

  15. Slide 15: Agenda

    Agenda o Affymetrix: The Company o The Power of Photolithography o Products o Customers, Markets, & Business Models o Working Together o Human Resources o Next Steps and Q&A

  16. Slide 16: Affymetrix: The Company

    Affymetrix: The Company The Power of Photolithography Products Customers, Markets, & Business Models Working Together Human Resources Next Steps and Q&A

  17. Slide 17: Expression Variability / Sequence Variability

    > Expression Variability mRNA Analysis) rer iss AIA All iB sequence Variability Resequencing >: Basic & Clinical R&D + Academic Pharma R&D Molecular Dx + Emerging Markets + Testing & Identification

  18. Slide 18: From Sequence to Function

    KG From Sequence to Function The Wry Ahead fig 1 fun users eig dried yt CODE ple pha. The nated thos ae ing tery ert pes of ‘Setond canes ston gesone ual fee iano ‘Science, Yol 208, sue 5698, 636-640 , 22 October 2004

  19. Slide 19: Affymetrix Product Lines

    Affymetrix Product Lines The Way Ahead.” AS GeneChip® Expression Array Products EUKARYA Bam Beams ‘Sequence Databases xia OascineExprnson Ara

  20. Slide 20: Customer Workflow: Understanding Genetics of Disease

    AFFYMET! Affymetrix Product Lines The Way Ahead.” KC. Customer Workflow: Understanding Genetics of Disease Description Product Linkage & association EEE Targeted Reduce to candidate + MIP genotyping SNPsiregions/genes Perlegen 10K, 100K, 500K+ MIP. Scan whole genome Sequence | Identiy candidate cust

  21. Slide 21: GCS3000Dx Launch

    -erstanaing GCS3000Dx Launch World's First Diagnostic Pharmacogenomic Microarray System for European Union & North America ‘GCS 3000Dx System AmpliChip CYP450 Test

  22. Slide 22: Affymetrix Product Lines

    Affymetrix Product Lines Fluidics Station GCS 2000Dx HT Scanner

  23. Slide 23: Formed Perlegen to Drive New Applications

    Formed Perlegen to Drive New Applications

  24. Slide 24: Formed Perlegen to Drive New Applications

    ned Perlegen to Drive New Applications JAFFYMETRIX, — | Supply wafers & chips LD pp ly, P: , Dl ———y PERLE! Generate Information Inforrlation for chipidesign _ < drug development eS Association studies [ma] & biological research for

  25. Slide 25: Agenda

    Agenda o Affymetrix: The Company o The Power of Photolithography o Products o Customers, Markets, Business Models o Working Together o Human Resources o Next Steps and Q&A

  26. Slide 26: Agenda

    The Wry Ahead Agenda Affymetrix: The Company The Power of Photolithography Products Customers, Markets, Business Models Working Together Human Resources Next Steps and Q&A

  27. Slide 27: Molecular Diagnostics, Emerging Markets

    Molecular Diagnostics, Emerging Markets Ooo € Wate | ParAllele| >

  28. Slide 28: GeneChip Technology in Academic Centers

    The Wry Ahead SELECTED CENTERS + Sanger Institute + Harvard University ‘Dana Farber Ca Insite = MIKINCL + Stanford University + Columbia University Canadian Gene! Diseases Network sity of Colorado =H ing Hart Cystic Fi Foundation Duke University RIKEN GeneChip® Technology in Academic Centers

  29. Slide 29: GeneChip Technology in Drug Development

    AFFYMETRIX Discovery) Validation and) Pre-Ciinicalland) Optimization) Glinicall trials; + ~200 publications referencing GeneChip® technology in drug development + Schering-Plough Abbott Sankyo a6 . ; Roc! + >650 clinical trials ongoing or Weeki 8 completed for 2004-05 involving 5 GeneChip® technolog

  30. Slide 30: PbA: Powered by Affymetrix Partnership Model

    PbA: Powered by Affymetrix Partnership Model o 'Intel Inside' o Non-exclusive relationships o PbA partner develops & commercializes products Roche o Combines the power of two industry gold standards: PCR & GeneChip® technology for human diagnostic products Veridex LLC o Develops & commercializes bro

  31. Slide 31: Emerging Markets: Applied Testing Applications

    Emerging Markets: Applied Testing Applications

  32. Slide 32: Development of Standards & Controls

    Development of Standards & Controls Leadership in industry, academic, and national agency consortia

  33. Slide 33: Affymetrix Public Policy Priorities

    Affymetrix Public Policy Priorities o Genetic privacy and non-discrimination o Government funding of translational research o IP: no patents on naturally occurring genes o Formalized research exemption

  34. Slide 34: Affymetrix Public Policy Priorities

    Affymetrix Public Policy Priorities Genetic privacy and non-discrimination Government funding of translational research IP: no patents on naturally occurring genes Formalized research exemption

  35. Slide 35: A New Paradigm in NIH Funding

    A New Paradigm in NIH Funding A New Paradigm in NIH Funding o Harmonization of Clinical Research Regulatory Processes o Integration of Clinical Research Networks o Enhancing Clinical Research Workforce Training o National Electronic Clinical Trials & Research System (NECTAR) o Regional Translational

  36. Slide 36: Growing International Biobanking Activities

    Growing International Biobanking Activities US efforts include: o Mayo Clinic o Marshfield Personalized Medicine o Framingham Heart Study o National Childrens Study o Nurses' Health Study o American Cancer Society CPS-II o CDC NHANES III

  37. Slide 37: Affymetrix & Translational Medicine

    Affymetrix & Translational Medicine Affymetrix technology becomes the standard in genetic profiling within biobanks

  38. Slide 38: Agenda

    Agenda o Affymetrix: The Company o The Power of Photolithography o Products Customers & Markets o Working Together Human Resources o Next Steps and Q&A

  39. Slide 39: Affymetrix: The Company

    Affymetrix: The Company The Power of Photolithography Products Customers & Markets Working Together Human Resources Next Steps and Q&A

  40. Slide 40: Why We Think This Makes Sense

    Why We Think This Makes Sense Affymetrix brings: o Industry-leading DNA business (largest and fastest-growing) o Universal market presence, reach and brand ParAllele brings: o Innovative, leading genetics assays o Capabilities for both products and services o Talented, versatile people Together, we

  41. Slide 41: Customer Workflow: Understanding Genetics of Disease

    Customer Workflow: Understanding Genetics of Disease

  42. Slide 42: Our Business Vision

    Our Business Vision o Fundamental vision: More information enables customers to make better decisions - Customers used to 100 SNPs or 700 bases - More information too expensive or hard to analyze - We need to deliver more complete information effectively and affordably o Enable whole genome DNA anal

  43. Slide 43: Evolution of Our Relationship

    Evolution of Our Relationship (Our Perspective) Get to know each other 2003 1st agmt (Joint Dev) Friendly, but uncommitted Date 2004 2nd agmt (Joint Dev & Cmml) Cautiously optimistic, but still long-term uncommitted Are we right for each other? 2005 Discussing wide range of possibilities Enthusiasti

  44. Slide 44: What to Expect From Us

    What to Expect From Us We WILL o Drive business growth faster than either of us could have alone o Seek to establish this assay as the market standard for genotyping (and other applications) o Create opportunities for you to lead as part of the market leader We WON'T o Know all the answers -- we nee

  45. Slide 45: Key Near-Term Priorities

    Key Near-Term Priorities o Launch 1st generation system (complete) o Develop clear joint plan for next generation system - Marketing drives requirements - Product development drives workplan o Invest in the business - Technology development - New application development - Standard panels o Prioritiz

  46. Slide 46: Agenda

    Agenda o Affymetrix: The Company o The Power of Photolithography o Products o Customers & Markets o Working Together o Human Resources o Next Steps and Q&A

  47. Slide 47: Affymetrix: The Company

    Affymetrix: The Company The Power of Photolithography Products Customers & Markets Working Together Human Resources Next Steps and Q&A

  48. Slide 48: Affymetrix Human Resources

    AFEYMETRIX, The Way Ahead” Affymetrix Human Resources

  49. Slide 49: HR Philosophy

    AFEYMETRI HR Philosophy = Market Competitive Compensation and Benefits = Believe in investing in training and development = HR partners are experienced and accessible

  50. Slide 50: Compensation Philosophy

    WOE The Wry Ahead = To ensure that employees’ total compensation is aligned with their performance and value to the organization as well as the external market — We Pay for Performance — We pay according to competitive market trends — We focus on Total Compensation = Base Pay (experience & skills, r

  51. Slide 51: Quick Benefits Comparison

    Quick Benefits Comparison PARALLELE BENEFITS AFFYMETRIX BENEFITS Eligibility Must work 30 hours Eligibility Must work 20 hours BENEFIT EMPLOYEE COST DEPENDENT COST COMMENTS BENEFIT EMPLOYEE COST DEPENDENT COST COMMENTS Medical Medical Blue Cross PPO 0% 50% Blue Shield PPO (California and Non-Califor

  52. Slide 52: Agenda

    Agenda || Affymetrix: The Company || The Power of Photolithography || Products || Customers, Markets, & Business Models || Working Together || Human Resources || Next Steps and Q&A

  53. Slide 53: Next Steps

    Next Steps || Day to Day: "business as usual" to deliver on our mutual goals & objectives || Integration team has been defined, with representation from both Affymetrix and ParAllele || Be patient with each other! || The teamwork continues!

  54. Slide 54: Affymetrix & ParAllele: Driving the Genetic Revolution

    Affymetrix & ParAllele: Driving the Genetic Revolution

  55. Slide 55: AFFYMETRIX, d

    AFFYMETRIX, d AG2 wero ma —_ Basic Research Personalized medicine

  56. Slide 56: Questions?

    ae, AFEYMETRIX, The Way Ahead” Questions?

Affymetrix — Merger or Acquisition (May 2005) on 6ix